Alzheimer’s disease drug development pipeline: 2024
Keywords: Alzheimer’s disease, amyloid, biomarkers, clinical trials, Common Alzheimer’s Disease Research Ontology (CADRO), drug development, inflammation, pharmaceutical companies, repurposed drugs, synaptic function, tau Authors: Jeffrey Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Fonseca, Feixiong Cheng Affiliations: Chambers‐Grundy Center for Transformative Neuroscience Department of Brain Health School of Integrated Health Sciences University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA; Genomic Medicine Institute Lerner Research Institute, Cleveland Clinic Cleveland Ohio USA; Howard R Hughes College of Engineering Department of
This article is available to registered members
Create a free account to access our full library of peer-reviewed research on medical cannabis.
Join — it's freeAlready a member? Log in